These clots block blood flow and can damage vital organs, most frequently the kidneys, but also the heart and brain.
Newer agents, such as Ravulizumab (a long-acting C5 inhibitor), have eased the burden by reducing infusion frequency from every two weeks to every eight weeks, but the core questions of cost and duration of therapy remain at the forefront of nephrology discourse. atypical hemolytic uremic syndrome